PET disease extent in EAU BCR low-risk patients, EAU BCR high-risk patients, and BCP patients (A) and predictors of PET M1 disease (B). OR = odds ratio. Image courtesy of Justin Ferdinandus, Wolfgang P. Fendler, Andrea Farolfi, et al.

January 24, 2022 — New research has confirmed the accuracy of the novel European Association of Urology (EAU) risk classification system that groups prostate cancer patients based on their risk of recurrence. Prostate-specific membrane antigen (PSMA) PET imaging of men with prostate cancer validated the EAU groupings and provided insights that could further refine risk assessment for patients. This study was published in the January issue of The Journal of Nuclear Medicine.

The diagnostic workup of prostate cancer has changed rapidly over the past few years. Recently, the EAU introduced a clinical system separating patients with rising PSA values after first-line therapy (prostate surgery or radiation) into groups of those with high risk and those with low risk for development of metastases. Shortly after this, the U.S. Food and Drug Administration approved 68Ga-PSMA-11 as the first PET drug to target the PSMA for men with prostate cancer.

“Given the growing availability of PSMA-directed PET imaging, our study sought to assess disease in patients based on the EAU classifications while using PSMA PET to identify subgroups of patients, such as those with undetectable, locoregional or distant metastatic disease,” said Justin Ferdinandus, MD, nuclear medicine physician at University Hospital in Essen, Germany.

The multicenter, international study analyzed PSMA PET scans of nearly 2,000 patients with prostate cancer and rising PSA levels. Patterns of disease spread on PSMA PET imaging were used to classify prostate cancer patients into both low- and high-risk groups. High-risk groups were found to have higher rates of metastatic disease on PSMA PET compared to low-risk groups. However, PSMA PET also found metastatic disease in low-risk and no disease in high-risk patients.

“Our study underscores the utility of the EAU risk groups to determine risk of metastasis in biochemically recurrent prostate cancer. But not every high-risk patient has metastases and not every low-risk patient has locoregional or no disease,” said Wolfgang Fendler, MD, nuclear medicine physician at University Hospital in Essen.

He continued, “The ultimate aim of imaging is to provide the right treatment for each patient. As evidenced in this research, the accuracy of PSMA PET is essential to improve stratification and potentially outcomes both in low-risk and high-risk settings.” 

For more information: www.snmmi.org

Related prostate cancer content:

VIDEO: MRI-Linac and PSMA PET Imaging Technologies Aids Therapy at GenesisCare

FDA Approves First Commercially Available PSMA PET Imaging Agent for Prostate Cancer

PSMA-Targeted Radiotracer Pinpoints Metastatic Prostate Cancer Across Anatomic Regions

Related Content

News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Radiopharmaceuticals and Tracers

May 16, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time May 16, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Focused Ultrasound Therapy

May 12, 2022 — Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for ...

Time May 12, 2022
arrow
News | Nuclear Imaging

May 9, 2022 — Novartis announced a temporary, voluntary suspension of production at its radioligand therapy production ...

Time May 09, 2022
arrow
News | Proton Therapy

May 5, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time May 05, 2022
arrow
News | Coronavirus (COVID-19)

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a ...

Time May 04, 2022
arrow
News | Radiation Therapy

May 4, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) ...

Time May 04, 2022
arrow
News | Quality Assurance (QA)

May 3, 2022 — Sun Nuclear Corporation, a wholly-owned subsidiary of Mirion Technologies, Inc., today announced the ...

Time May 03, 2022
arrow
Subscribe Now